Liquid biopsy provides new insights into gastric cancer

Guimarães, Camila Tavares Uchôa; Martins, Nina Nayara Ferreira; Oliveira, Kelly Cristina da Silva; Almeida, Caroline Martins; Pinheiro, Thayanne Macedo; Gigek, Carolina Oliveira; Cavalléro, Sandro Roberto de Araújo; Assumpção, Paulo Pimentel de; Smith, Marı́lia de Arruda Cardoso; Burbano, Rommel Rodrı́guez; Calcagno, Danielle Queiroz

doi:10.18632/oncotarget.24540

Cited by 31 publications

(34 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies have been performed evaluating cell free DNA in plasma/serum of GAC patients. 31,39,41,[48][49][50][51][52] In our study, 40% of the patients had the same tumor-biopsy TP53 mutations found in their plasma samples. In agreement with the literature, tumor-derived mutation frequencies in our cohort were higher in patients with stages III and IV.…”

Section: Discussionsupporting

confidence: 71%

See 1 more Smart Citation

Identification of DNA mutations in gastric washes from gastric adenocarcinoma patients: Possible implications for liquid biopsies and patient follow‐up

Pizzi

Bartelli

Pelosof

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

Whereas cancer patients have benefited from liquid biopsies, the scenario for gastric adenocarcinoma (GAC) is still dismal. We used next‐generation deep sequencing of TP53—a highly mutated and informative gene in GAC—to assess mutations in tumor biopsies, plasma (PL) and stomach fluids (gastric wash—GW). We evaluated their potential to reveal tumor‐derived mutations, useful for monitoring mutational dynamics at diagnosis, progression and treatment. Exon‐capture libraries were constructed from 46 patients including tumor biopsies, GW and PL pre and post‐treatment (196 samples), with high vertical coverage >8,000×. At diagnosis, we detected TP53 mutations in 15/46 biopsies (32.6%), 7/46 GW‐ (15.2%) and 6/46 PL‐samples (13%). Biopsies and GW were concordant in 38/46 cases (82.6%) for the presence/absence of mutations and, furthermore, four GW‐exclusive mutations were identified, suggesting tumor heterogeneity. Considering the combined analysis of GW and PL, TP53 mutations found in biopsies were also identified in 9/15 (60%) of cases, the highest detection level reported for GAC. Our study indicates that GW could be useful to track DNA alterations, especially if anchored to a comprehensive gene‐panel designed for this malignancy.

show abstract

Section: Discussionsupporting

confidence: 71%

“…Some studies have been performed evaluating cell free DNA in plasma/serum of GAC patients . In our study, 40% of the patients had the same tumor‐biopsy TP53 mutations found in their plasma samples.…”

Section: Discussionmentioning

confidence: 51%

Identification of DNA mutations in gastric washes from gastric adenocarcinoma patients: Possible implications for liquid biopsies and patient follow‐up

Pizzi

Bartelli

Pelosof

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…One of the potential solutions to this problem is liquid biopsy, a less invasive tool which can provide real-time insights into the tumor. Various blood-based surrogate markers including circulating DNA, miRNA, extracellular vesicles, platelets, and CTCs have been studied for liquid biopsy in order to predict responders to a certain therapy [50,117]. Among these, CTCs, with their newly discovered clinical significance, could contribute additionally to the perspective of cancer precision medicines from prognosis to real-time monitoring, therapeutic targets, and drug discovery ( Figure 2).…”

Section: Discussionmentioning

confidence: 99%

Emerging Role of Circulating Tumor Cells in Gastric Cancer

Huong

Gurshaney

Bình

et al. 2020

Cancers

View full text Add to dashboard Cite

With over 1 million incidence cases and more than 780,000 deaths in 2018, gastric cancer (GC) was ranked as the 5th most common cancer and the 3rd leading cause of cancer deaths worldwide. Though several biomarkers, including carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9), and cancer antigen 72-4 (CA72-4), have been identified, their diagnostic accuracies were modest. Circulating tumor cells (CTCs), cells derived from tumors and present in body fluids, have recently emerged as promising biomarkers, diagnostically and prognostically, of cancers, including GC. In this review, we present the landscape of CTCs from migration, to the presence in circulation, biologic properties, and morphologic heterogeneities. We evaluated clinical implications of CTCs in GC patients, including diagnosis, prognosis, and therapeutic management, as well as their application in immunotherapy. On the one hand, major challenges in using CTCs in GC were analyzed, from the differences of cut-off values of CTC positivity, to techniques used for sampling, storage conditions, and CTC molecular markers, as well as the unavailability of relevant enrichment and detection techniques. On the other hand, we discussed future perspectives of using CTCs in GC management and research, including the use of circulating tumor microembolies; of CTC checkpoint blockade in immunotherapy; and of organoid models. Despite the fact that there are remaining challenges in techniques, CTCs have potential as novel biomarkers and/or a non-invasive method for diagnostics, prognostics, and treatment monitoring of GC, particularly in the era of precision medicine.

show abstract

“…In addition to CTCs, ctDNA has been found in CTC-negative patients. Hence, ctDNA is discussed as a potential screening marker as well, even if the sensitivity seems lower in comparison to CTC detection [44,45]. In contrast, the CancerSEEK platform claims to detect eight different cancer entities with a sensitivity of 70% by ctDNA analysis of peripheral blood [46].…”

Section: Ctcs As Screening Toolmentioning

confidence: 99%

Clinical Significance of Circulating Tumor Cells in Gastrointestinal Carcinomas

et al. 2020

View full text Add to dashboard Cite

The idea of a liquid biopsy to screen, surveil and treat cancer patients is an intensively discussed and highly awaited tool in the field of oncology. Despite intensive research in this field, the clinical application has not been implemented yet and further research has to be conducted. However, one component of the liquid biopsy is circulating tumor cells (CTCs) whose potential for clinical application is evaluated in the following. CTCs can shed from primary tumors to the peripheral blood at any time point during the progress of a malignant disease. Following, one single CTC can be the origin for distant metastasis at later cancer stage. Thus, CTCs have great potential to either be used in cancer diagnostics and patient stratification or to function as a target for new therapeutic approaches to stop tumor dissemination and metastasis at the very early beginning. Due to the biological fundamental role of CTCs in tumor progression, here, we provide an overview of CTCs in gastrointestinal cancers and their potential use in the clinical setting. In particular, we discuss the usage of CTC for screening and stratifying patients’ risk. Moreover, we will discuss the potential role of CTCs for treatment specification and treatment monitoring.

show abstract

Liquid biopsy provides new insights into gastric cancer

Cited by 31 publications

References 101 publications

Identification of DNA mutations in gastric washes from gastric adenocarcinoma patients: Possible implications for liquid biopsies and patient follow‐up

Identification of DNA mutations in gastric washes from gastric adenocarcinoma patients: Possible implications for liquid biopsies and patient follow‐up

Emerging Role of Circulating Tumor Cells in Gastric Cancer

Clinical Significance of Circulating Tumor Cells in Gastrointestinal Carcinomas

Contact Info

Product

Resources

About